Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) related to its sale to Angelini Pharma S.p.A. Under the terms of the proposed transaction Catalyst shareholders are expected to receive $31.50 per share in cash.
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) related to its sale to Angelini Pharma S.p.A. Under the terms of the proposed transaction Catalyst shareholders are expected to receive $31.50 per share in cash.